Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019616 | 0.96 | ALDH1A1 (0.77) | ALDH1A1TSHRNPSR1HPGDMEN1 | |
| SCHEMBL24019582 | 0.95 | ALDH1A1 (0.79) | ALDH1A1TSHRNPSR1HPGDMEN1 | |
| SCHEMBL24019617 | 0.83 | NPSR1 (0.71) | ALDH1A1NPSR1HPGDMEN1KMT2A | |
| SCHEMBL21952044 | 0.83 | MAPT (0.56) | ALDH1A1TSHRNPSR1HPGDMEN1 | |
| SCHEMBL24209779 | 0.82 | KMT2A (0.76) | ALDH1A1NPSR1HPGDMEN1KMT2A | |
| SCHEMBL25609885 | 0.82 | ALDH1A1 (0.58) | ALDH1A1TSHRNPSR1HPGDMEN1 | |
| SCHEMBL24209903 | 0.81 | NPSR1 (0.68) | ALDH1A1NPSR1HPGDMEN1KMT2A | |
| SCHEMBL24210088 | 0.81 | KMT2A (0.83) | ALDH1A1NPSR1HPGDMEN1KMT2A | |
| SCHEMBL25609962 | 0.81 | NPSR1 (0.67) | ALDH1A1NPSR1HPGDMEN1KMT2A | |
| SCHEMBL21951986 | 0.80 | MAPT (0.71) | ALDH1A1TSHRNPSR1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| WO-2021229035-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2021-11-18 | — | — | WO | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | ALDH1A1 1206/4885TSHR 4635/4885NPSR1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.